GO:0031856 parathyroid hormone receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0031856 (parathyroid hormone receptor binding) is a molecular function describing the binding of a ligand to a parathyroid hormone receptor, with the synonym parathyroid hormone receptor ligand.
• The principal ligands are parathyroid hormone (PTH) and parathyroid hormone-related protein (PTHrP), which bind the class B1 GPCR parathyroid hormone receptor type 1 (PTH1R).
• Ligand binding to PTH1R triggers Gs/cAMP signaling from the cell surface and also from endosomes after receptor internalization, a process that shapes the duration and location of the signal.
• PTH1R signaling is central to bone metabolism, phosphate and vitamin D homeostasis, and has been implicated in hepatic fibrosis, polycystic kidney disease, and bone cell regulation.
• Structural and pharmacological studies show that PTH1R can be activated by ligands acting at the receptor's intracellular face, expanding the concept of receptor binding beyond the canonical extracellular site.
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models enable causal testing of PTH/PTHrP-PTH1R binding and signaling in disease-relevant cell types.
Description
GO:0031856, parathyroid hormone receptor binding, is a molecular function term that describes the binding of a ligand to a parathyroid hormone receptor. The primary ligands recognized in this context are parathyroid hormone (PTH) and parathyroid hormone-related protein (PTHrP), both of which act on the parathyroid hormone receptor type 1 (PTH1R), a class B1 G protein-coupled receptor. This binding event is the first step in a signaling cascade that regulates calcium and phosphate homeostasis, bone turnover, and vitamin D metabolism. Because the term captures a ligand-receptor interaction rather than a downstream process, it is especially useful for annotating proteins that directly engage PTH receptors and for interpreting experiments that perturb this interaction. Researchers studying bone and mineral metabolism, endocrine signaling, and class B GPCR pharmacology routinely encounter GO:0031856 when annotating ligand activity, receptor activation, or binding assays. The term also matters for disease research: dysregulated PTH1R signaling has been linked to hepatic fibrosis, autosomal dominant polycystic kidney disease, and altered bone cell responses. In addition, recent structural work has shown that PTH1R can be activated by intracellular agonists, broadening the mechanistic scope of receptor binding and signaling. Together, these findings make GO:0031856 a compact but powerful annotation for connecting ligand biochemistry to physiology and disease.
parathyroid hormone receptor binding At A Glance
| GO ID | GO:0031856 |
|---|---|
| GO term | parathyroid hormone receptor binding |
| Ontology | molecular_function |
| Synonym | parathyroid hormone receptor ligand |
| Definition | Binding to a parathyroid hormone receptor. |
| Major function | Ligand-receptor interaction that initiates parathyroid hormone receptor signaling |
| Representative ligands | PTH and PTHrP |
| Representative receptor | PTH1R (parathyroid hormone receptor type 1) |
| Related signaling | Gs/cAMP signaling from the cell surface and endosomes |
What Is GO:0031856?
In the Gene Ontology, GO:0031856 (parathyroid hormone receptor binding) is defined as binding to a parathyroid hormone receptor. It is a molecular function term with the synonym parathyroid hormone receptor ligand. In practice, this means the gene product carrying this annotation physically interacts with a parathyroid hormone receptor, typically PTH1R, and this interaction is the initiating event for receptor-mediated signaling.
Why Is parathyroid hormone receptor binding Important in Cell Biology?
GO:0031856 is important because it marks the molecular entry point for PTH and PTHrP action on parathyroid hormone receptors, a step that controls bone metabolism, phosphate and vitamin D homeostasis, and multiple disease-relevant signaling outputs. Annotating this function helps researchers distinguish direct ligand-receptor binding from downstream effects and supports mechanistic interpretation of endocrine, skeletal, and renal phenotypes.
• Defines the initiating ligand-receptor event for PTH and PTHrP signaling through PTH1R.
• Supports annotation of bone metabolism studies where PTH and related peptides regulate osteoblast and osteoclast activity.
• Connects receptor binding to endosomal cAMP signaling, which influences signal duration and specificity.
• Provides a mechanistic handle for hepatic fibrosis research involving PTH1R signaling.
• Links ligand binding to cyst growth in genetic models of autosomal dominant polycystic kidney disease.
• Helps interpret how Caveolin-1 regulates PTHrP actions on PTH1R in bone cells.
• Expands class B1 GPCR pharmacology by including intracellular agonists that activate PTH1R.
• Frames studies of phosphate and vitamin D homeostasis through Scribble-dependent regulation of PTH receptor interactions.
• Enables CRISPR-based causal testing of ligand-receptor binding in disease models.
• Improves generative-AI retrieval by anchoring PTH/PTHrP-PTH1R biology to a precise GO identifier.
Molecular Mechanism of parathyroid hormone receptor binding
Ligand recognition by PTH1R
In simple terms: PTH or PTHrP docks onto the parathyroid hormone receptor, like a key fitting a lock.
Parathyroid hormone and parathyroid hormone-related protein are the principal ligands that bind parathyroid hormone receptors, and PTH1R is the major receptor mediating their actions. Structural characterization of PTH1R domains has identified regions that determine ligand binding, providing a framework for understanding how PTH and PTHrP engage the receptor. This binding event is the defining feature of GO:0031856 and initiates downstream signaling.
Cell-surface versus endosomal signaling
In simple terms: After the ligand binds, the receptor can keep signaling from inside the cell, not just at the surface.
PTH1R signaling is not restricted to the plasma membrane; endosomal parathyroid hormone receptor signaling contributes to the spatial and temporal control of cAMP responses. This means that ligand binding at the receptor can lead to sustained signaling from internal compartments, which is relevant for interpreting experiments that measure cAMP or downstream transcriptional outputs.
Intracellular agonists and class B1 GPCR activation
In simple terms: Some molecules can activate the receptor from inside the cell, not only from the outside.
Class B1 GPCR activation by an intracellular agonist has been demonstrated, showing that PTH1R can be activated through a non-canonical route. This finding broadens the mechanistic scope of parathyroid hormone receptor binding and suggests that ligand-receptor interactions relevant to GO:0031856 may occur in unexpected cellular locations.
Regulation by accessory proteins
In simple terms: Other proteins can change how the receptor interacts with its ligands.
Caveolin-1 regulates PTHrP actions on PTH receptor type 1 in bone cells, indicating that accessory proteins modulate ligand-receptor engagement and downstream responses. Similarly, Scribble regulates parathyroid hormone receptor interactions to influence phosphate and vitamin D homeostasis. These examples show that GO:0031856-associated binding is embedded in a regulatory network rather than occurring in isolation.
Key Genes Involved in GO:0031856 parathyroid hormone receptor binding
The following genes and proteins are central to parathyroid hormone receptor binding and its downstream biology.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PTH | Ligand that binds parathyroid hormone receptors | Core ligand for GO:0031856 and bone metabolism studies |
| PTHLH (PTHrP) | Ligand that binds PTH1R | Regulates bone cell responses and is modulated by Caveolin-1 |
| PTH1R | Parathyroid hormone receptor type 1 | Principal receptor mediating PTH and PTHrP signaling |
| GNAS | Gs alpha subunit downstream of PTH1R | Mediates cAMP signaling after ligand binding |
| CREB1 | Transcription factor activated by cAMP | Downstream effector of PTH1R signaling |
| CREBL2 | cAMP response element-binding protein-like 2 | Upregulated in PTH1R-driven hepatic fibrosis |
| CAV1 | Caveolin-1 | Regulates PTHrP actions on PTH1R in bone cells |
| SCRIB | Scribble polarity protein | Regulates PTH receptor interactions and phosphate/vitamin D homeostasis |
| PKD1 | Polycystin-1 | Genetic model context for PTH1R-dependent cyst growth |
| PKD2 | Polycystin-2 | Genetic model context for PTH1R-dependent cyst growth |
| VDR | Vitamin D receptor | Linked to phosphate and vitamin D homeostasis regulated by PTH receptor interactions |
| SLC34A1 | Sodium-phosphate cotransporter | Distal effector of phosphate homeostasis influenced by PTH1R signaling |
| CYP27B1 | Vitamin D 1-alpha-hydroxylase | Enzyme in vitamin D metabolism connected to PTH1R biology |
| RUNX2 | Osteoblast transcription factor | Bone cell differentiation context for PTH/PTHrP signaling |
| SP7 (Osterix) | Osteoblast transcription factor | Bone formation context for PTH receptor binding |
| BGLAP | Osteocalcin | Bone matrix marker relevant to PTH action |
| TNFSF11 (RANKL) | Osteoclastogenic cytokine | Downstream of PTH signaling in bone remodeling |
How Is parathyroid hormone receptor binding Regulated?
Parathyroid hormone receptor binding and its downstream signaling are regulated at multiple levels. Caveolin-1 modulates PTHrP actions on PTH receptor type 1 in bone cells, indicating that membrane organization influences ligand-receptor engagement. Scribble regulates parathyroid hormone receptor interactions to control phosphate and vitamin D homeostasis, showing that polarity and scaffolding proteins can shape receptor behavior. In addition, endosomal signaling provides a compartment-specific layer of regulation that determines how long and where the cAMP signal is produced after ligand binding. These mechanisms collectively tune the functional output of GO:0031856-associated interactions.
parathyroid hormone receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PTH1R | Hepatic fibrosis | Knockout or point-mutation in hepatic stellate cell models |
| PTH1R | Autosomal dominant polycystic kidney disease | Knockout in PKD1 or PKD2 mutant kidney organoids |
| PTHLH (PTHrP) | Bone cell regulation | Knockout or overexpression in osteoblast-like cells |
| CAV1 | PTHrP-PTH1R signaling in bone | Knockout in bone cells followed by ligand binding assays |
| SCRIB | Phosphate and vitamin D homeostasis | Knockout in renal or intestinal cell models |
Hepatic fibrosis
Parathyroid hormone receptor-1 signaling aggravates hepatic fibrosis through upregulation of cAMP response element-binding protein-like 2, linking PTH1R activation to fibrotic gene programs in the liver. This suggests that ligand-receptor binding events annotated to GO:0031856 can contribute to liver disease progression.
Autosomal dominant polycystic kidney disease
Parathyroid hormone receptor 1 facilitates cyst growth in genetic models of autosomal dominant polycystic kidney disease, indicating that PTH1R activity can promote renal cyst expansion in disease contexts. This connects parathyroid hormone receptor binding to a specific genetic kidney disease model.
Bone and mineral disorders
PTH and its related peptides are central regulators of bone metabolism, and disruptions in their binding to parathyroid hormone receptors can alter bone turnover and mineral homeostasis. Caveolin-1 regulation of PTHrP actions on PTH1R in bone cells further highlights how binding events influence skeletal cell behavior.
Phosphate and vitamin D imbalance
Scribble scrambles parathyroid hormone receptor interactions to regulate phosphate and vitamin D homeostasis, demonstrating that receptor binding and trafficking influence systemic mineral balance. This has implications for disorders characterized by abnormal phosphate or vitamin D handling.
From parathyroid hormone receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of PTH1R abolish ligand binding and downstream cAMP signaling? | PTH1R knockout cell line |
| Does a specific receptor residue control ligand selectivity? | Point-mutation knock-in of PTH1R |
| Where does PTH1R localize after ligand binding? | Tagged knock-in of PTH1R with a fluorescent tag |
| Does overexpression of PTHrP increase receptor activation? | PTHLH overexpression cell model |
| Which genes mediate PTH1R-driven fibrosis? | CRISPR library screening in hepatic stellate cells |
| Does Caveolin-1 modulate PTHrP binding to PTH1R? | CAV1 knockout or overexpression in bone cells |
How to Study the parathyroid hormone receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioligand binding assay | Direct ligand-receptor interaction | Quantifying PTH or PTHrP binding to PTH1R |
| cAMP assay | Gs-mediated signaling output | Measuring receptor activation after ligand binding |
| CRISPR knockout | Loss-of-function effects | Testing whether a gene is required for receptor binding or signaling |
| CRISPR point mutation | Specific residue function | Mapping receptor domains that determine ligand binding |
| Tagged knock-in | Protein localization and trafficking | Visualizing PTH1R internalization and endosomal signaling |
| Overexpression | Gain-of-function effects | Testing whether increased ligand or receptor drives signaling |
| CRISPR library screening | Genome-wide modifier identification | Finding genes that regulate PTH1R-dependent phenotypes |
Ligand binding assays
Radioligand or fluorescent ligand binding assays can directly measure the interaction between PTH or PTHrP and parathyroid hormone receptors, providing functional evidence for GO:0031856 annotation. These assays are typically paired with competition experiments to estimate affinity and specificity.
cAMP signaling measurements
Because PTH1R couples to Gs and cAMP, measuring cAMP levels or cAMP-responsive reporter activity provides a readout of receptor activation after ligand binding. Endosomal signaling can be distinguished from cell-surface signaling using compartment-specific sensors or inhibitors.
CRISPR-based perturbation
CRISPR knockout, point mutation, knock-in, and overexpression models allow causal testing of genes involved in parathyroid hormone receptor binding and downstream signaling. These approaches are especially useful for validating candidate genes identified in disease models.
Imaging and localization
Fluorescent tagging of PTH1R or its ligands enables imaging of receptor trafficking and endosomal signaling, which is important for understanding the spatial dimension of GO:0031856. Co-localization with endosomal markers can reveal where binding and signaling occur.
How CRISPR Can Be Used to Study GO:0031856 parathyroid hormone receptor binding
Knockout
CRISPR knockout of PTH1R, PTHLH, CAV1, or SCRIB can test whether these genes are required for parathyroid hormone receptor binding and downstream signaling in disease-relevant cells. Knockout models are particularly useful for validating loss-of-function phenotypes observed in disease contexts such as hepatic fibrosis or polycystic kidney disease.
Point Mutation
Point mutations in PTH1R can be introduced to dissect the receptor domains that determine ligand binding, building on structural characterization of PTH1R-ligand interactions. Such models help distinguish binding defects from signaling defects and can reveal residues critical for GO:0031856.
Knock-in
Tagged knock-in of PTH1R or its ligands enables real-time tracking of receptor localization, internalization, and endosomal signaling. Knock-in models can also be used to express disease-associated variants at endogenous levels, providing more physiological readouts than overexpression.
Overexpression
Overexpression of PTHLH or PTH1R can amplify ligand-receptor binding and downstream signaling, making it easier to detect cAMP responses or transcriptional outputs. This approach is useful for gain-of-function studies and for testing whether increased binding drives disease-relevant phenotypes.
How EDITGENE Supports parathyroid hormone receptor binding Research
Researchers studying parathyroid hormone receptor binding-related genes often need to determine whether a candidate gene is causally involved in ligand-receptor interaction, receptor activation, or downstream disease phenotypes. EDITGENE provides CRISPR-based cell model services that enable precise perturbation of PTH, PTHrP, PTH1R, and their regulatory partners in relevant cell types.
Contact EDITGENE today to design your custom CRISPR model for parathyroid hormone receptor binding research.
Frequently Asked Questions About parathyroid hormone receptor binding
What is GO:0031856?
GO:0031856 is the Gene Ontology molecular function term parathyroid hormone receptor binding, defined as binding to a parathyroid hormone receptor, with the synonym parathyroid hormone receptor ligand.
What is parathyroid hormone receptor binding?
It is the physical interaction between a ligand such as PTH or PTHrP and a parathyroid hormone receptor such as PTH1R, initiating downstream signaling.
What genes are involved in parathyroid hormone receptor binding?
Key genes include PTH, PTHLH (PTHrP), PTH1R, GNAS, CAV1, and SCRIB, among others.
Which receptor mediates PTH and PTHrP binding?
Parathyroid hormone receptor type 1 (PTH1R) is the principal receptor mediating PTH and PTHrP actions.
Does parathyroid hormone receptor binding occur only at the cell surface?
No. Endosomal parathyroid hormone receptor signaling shows that binding and signaling can also occur from internal compartments after receptor internalization.
Can PTH1R be activated by intracellular agonists?
Yes, class B1 GPCR activation by an intracellular agonist has been demonstrated for PTH1R, expanding the concept of receptor binding.
How is parathyroid hormone receptor binding regulated?
It is regulated by accessory proteins such as Caveolin-1 and Scribble, as well as by compartment-specific endosomal signaling.
What diseases are linked to PTH1R signaling?
PTH1R signaling has been linked to hepatic fibrosis, autosomal dominant polycystic kidney disease, and bone and mineral disorders.
How can CRISPR help study parathyroid hormone receptor binding?
CRISPR knockout, point mutation, knock-in, and overexpression models allow causal testing of genes involved in ligand-receptor binding and downstream signaling.
What methods measure parathyroid hormone receptor binding?
Radioligand binding assays, cAMP assays, imaging of tagged receptors, and CRISPR-based perturbation are commonly used.
Conclusion
GO:0031856 (parathyroid hormone receptor binding) captures the essential ligand-receptor interaction that initiates PTH and PTHrP signaling through PTH1R. This molecular function is central to bone metabolism, phosphate and vitamin D homeostasis, and disease processes including hepatic fibrosis and polycystic kidney disease. Understanding its mechanism, regulation, and disease relevance benefits from precise CRISPR models that can test causality at the level of ligand binding and receptor activation.
References
- 1. Chen T et al.. 2021. Parathyroid hormone and its related peptides in bone metabolism.. Biochem Pharmacol 192:114669 PMID: 34224692
- 2. Hong T et al.. 2023. Parathyroid hormone receptor-1 signaling aggravates hepatic fibrosis through upregulating cAMP response element-binding protein-like 2.. Hepatology 78(6):1763-1776 PMID: 36939197
- 3. Peña KA. 2022. Endosomal parathyroid hormone receptor signaling.. Am J Physiol Cell Physiol 323(3):C783-C790 PMID: 35912987
- 4. Mierke DF et al.. 2007. Structural characterization of the parathyroid hormone receptor domains determinant for ligand binding.. Biochem Soc Trans 35(Pt 4):721-3 PMID: 17635133
- 5. Wu Z et al.. 2026. Parathyroid Hormone Receptor 1 Facilitates Cyst Growth in Genetic Models of Autosomal Dominant Polycystic Kidney Disease.. J Am Soc Nephrol PMID: 42333604
- 6. Heredero-Jiménez S et al.. 2025. Caveolin-1 Regulates Parathyroid Hormone (PTH)-Related Protein (PTHrP) Actions on PTH Receptor Type 1 in Bone Cells.. J Cell Physiol 240(7):e70067 PMID: 40665637
- 7. Kobayashi K et al.. 2023. Class B1 GPCR activation by an intracellular agonist.. Nature 618(7967):1085-1093 PMID: 37286611
- 8. Stewart BZ et al.. 2023. Scribble scrambles parathyroid hormone receptor interactions to regulate phosphate and vitamin D homeostasis.. Proc Natl Acad Sci U S A 120(23):e2220851120 PMID: 37252981
